Metastatic Calcification

Pathogenesis

Causes of hypercalcemia

1. Increased PTH activity
   • Primary hyperparathyroidism due to parathyroid adenoma/tumor
   • Ectopic production of PTH-related protein (PTHrP) by malignant tumors
2. Increased bone resorption
   • Multiple myeloma
   • Diffuse skeletal metastases, especially breast carcinoma
   • Paget disease of bone
   • Prolonged immobilization
3. Vitamin D-related disorders
   • Vitamin D intoxication
   • Sarcoidosis, where macrophages activate vitamin D precursors
   • Idiopathic infantile hypercalcemia (Williams syndrome)
4. Renal failure
   • Phosphate retention causes secondary hyperparathyroidism and favors calcium-phosphate deposition.

Common sites

• Gastric mucosa
• Kidneys, especially renal interstitium and tubules
• Lungs, especially alveolar walls
• Systemic arteries
• Pulmonary veins

Morphology

• Gross: fine, white, gritty granules or clumps.
• Microscopy: basophilic, granular calcium deposits in interstitial tissues and basement membranes. Deposits may be extracellular or intracellular.
• The deposits resemble dystrophic calcification morphologically, but their location in normal tissue and association with hypercalcemia distinguishes them.

Effects / clinical significance

• Lung: impaired gas exchange, respiratory insufficiency, radiologically visible calcification.
• Kidney: nephrocalcinosis, tubular/interstitial injury, and renal dysfunction.
• Blood vessels: reduced vascular compliance and ischemic injury in extensive disease.

Difference from dystrophic calcification

One-line exam conclusion

Recent advances in metastatic calcification

1. Earlier and more sensitive detection
   • High-resolution CT can detect pulmonary metastatic calcification as diffuse or nodular ground-glass opacities, often with subtle calcification.
   • 99mTc-MDP bone scintigraphy is increasingly used to demonstrate occult systemic deposits, particularly in dialysis patients. A small 2025 cohort found lung, joint, and skin involvement most frequently. Wang et al., 2025, PMID: 39747388
2. Focus on CKD-mineral and bone disorder
   • In chronic kidney disease, management now emphasizes serial assessment of phosphate, calcium, PTH, vitamin D, and avoidance of excess calcium loading.
   • Treatment aims at correction of the underlying abnormality with dietary phosphate restriction, dialysis optimization, phosphate binders, and calcimimetics where indicated. This is prevention or metabolic control, rather than a treatment that directly dissolves established deposits.
3. Recognition of vascular-calcification inhibitors
   • Recent work identifies reduced or disturbed activity of endogenous inhibitors such as fetuin-A, matrix Gla protein, pyrophosphate, magnesium, Klotho, and osteopontin in CKD-associated calcification.
   • These molecules may become biomarkers for earlier risk stratification and possible therapeutic targets. However, they are not yet established routine therapies.
     Systematic review, 2025, PMID: 40185382
4. Experimental targeted therapies
   • Soluble Klotho, microRNA-directed approaches to prevent osteogenic transformation of vascular smooth-muscle cells, and more selective phosphate-transport inhibitors are under preclinical or early translational investigation.
   • These approaches are promising but not standard clinical treatment.
5. Sodium thiosulfate
   • It has been tried in selected dialysis-associated calcification cases, especially when calciphylaxis overlaps with severe soft-tissue calcification.
   • Evidence for true metastatic calcification remains limited to small observational studies and case reports, so it should not be presented as established therapy. The 2025 scintigraphy cohort reported its use in 9 of 10 patients. Wang et al., 2025, PMID: 39747388

Exam-ready concluding line